key: cord-0691237-229cy5ik
authors: Lee, Anna; Nahm, Chung Hyun; Lee, Jin‐Soo; Lee, Mi‐Kyeong; Lee, Kyoung‐Ryul
title: Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
date: 2021-10-05
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24004
sha: 8c4c384b1fc4b8f0679080c4d29e7f49679c964c
doc_id: 691237
cord_uid: 229cy5ik

BACKGROUND: To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients. METHODS: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were measured using enzyme‐linked immunosorbent assay (ELISA) and multiplex flow immunoassay (MFIA) in hospitalized COVID‐19 patients (N = 105) and healthy controls (N = 38). Anti‐phosphatidylserine/prothrombin antibodies, calprotectin, and C‐reactive protein (CRP) levels were also measured. We assessed the potential correlation between calprotectin levels and various laboratory parameters that were measured during the hospitalization period. After stratifying COVID‐19 patients into two groups by their oxygenation status or acute respiratory distress syndrome presentation, the discriminatory performance of each biomarker was evaluated. RESULTS: A high proportion of COVID‐19 patients (29.5%, 31/105) had low aCL IgM titers that were detectable by ELISA but mostly below the detection limit of MFIA. Calprotectin levels in severe groups of COVID‐19 were significantly higher than those in non‐severe groups, while CRP levels revealed no significant differences. Serum calprotectin levels showed strong to moderate degree of correlation with other routinely used parameters including peak levels of CRP, ferritin, procalcitonin, BUN, and neutrophil‐to‐lymphocyte ratio, but a negative correlation with minimal lymphocyte count and CD4(+) T cells. The discriminatory performance was highest for calprotectin in discriminating severe groups of COVID‐19. CONCLUSIONS: Serum calprotectin levels were significantly elevated in severe COVID‐19 cases. The prevalence of clinically significant aPL did not differ. The link between calprotectin and inflammatory pathway in COVID‐19 may help improve the management and outcomes of COVID‐19 patients.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease . Although COVID-19 most commonly presents with influenza-like illness and viral pneumonia, its critical cases often have a profound hypercoagulable state leading to coagulopathy, and this leads to acute respiratory distress syndrome (ARDS) or multi-organ failure. 1 Recently, some researchers reported an important role of antiphospholipid antibodies (aPL) in thrombotic events in critical cases of COVID-19, 2 while others suggested a poor correlation between aPL and thrombotic events; therefore, its association with thrombotic events remains controversial. 3 Calprotectin (myeloid-related protein [MRP]8/14) is released under inflammatory conditions and is involved in neutrophil-related inflammatory processes. 4 Calprotectin levels in the blood are associated with poor clinical outcomes in COVID-19, especially in patients with severe pulmonary disease. 5 In this study, the authors measured aPL (anticardiolipin antibody [aCL] and anti-β2-glycoprotein I antibody [aβ2GPI]) in the sera of hospitalized COVID-19 patients using two different solidphase assays. While functional assays for aPL (i.e., lupus anticoagulant [LA]) were unavailable for this study, we performed anti-phosphatidylserine/prothrombin antibody (aPS/PT) assay as a surrogate test for LA. 6 We also assayed calprotectin and C-reactive protein (CRP) levels in the sera of hospitalized COVID-19 patients and assessed the possible relationship between oxygenation status and the lung involvement.

Between July 4, 2020, and November15, 2020, 105 hospitalized COVID-19 patients (60 women and 45 men with a mean age of 68.0 ± 18.8 years) and 38 healthy controls (21 females and 17 males with a mean age of 53.1 ± 12.5 years) were enrolled in this retrospective study. Overview of the characteristics of COVID-19 cases, including demographic features, comorbidities, therapy received, complications, treatment, and final outcome, are summarized in Table 1 

The data of the groups were expressed as medians and interquartile range (IQR), wherever appropriate. When two groups were compared, normally distributed data were analyzed using a two-sided t test, and skewed data were analyzed using the Mann-Whitney The Youden index optimal cutoff, sensitivity, and specificity were also evaluated. Data were analyzed using the MedCalc Statistical Software ver. 20.006 (Ostend, Belgium), and statistical significance was defined as p < 0.05. Figure 1A ). Although the background level of aCL IgM (MFIA) in COVID-19 patients was also higher than that of controls ( Figure 1B) , the difference was not statistically significant (p = 0.243) and most values were below the cutoff value.

A low degree of positive correlation (r = 0.3163, p = 0.001) was observed between MFIA and ELISA for aCL IgM ( Figure 1C ). However, the prevalence of aCL IgG/IgA (ELISA), β2GPI IgG/IgM (ELISA), and aPS/PT IgG/IgM (ELISA) was similar in COVID-19 cases and controls (p > 0.05) ( Table 2) . We did not find any association between aPL positivity and thrombotic events in COVID-19 patients.

The median (IQR) calprotectin levels in COVID-19 cases (N = 105)

were significantly higher than those in healthy controls (N = 38) 

When comparing calprotectin levels between oxygen therapy groups (R1 versus R2) or lung involvement groups (ARDS− versus ARDS+), calprotectin levels in group R2 or group ARDS+ were significantly higher than those in group R1 or group ARDS−, respectively ( Figure 2A ,B) ( Table 4 ). When comparing CRP levels between oxygen therapy groups (R1 versus R2) or lung involvement groups (ARDS− versus ARDS+), CRP levels did not reveal significant differences between groups R1 and R2 or groups ARDS− and ARDS+ ( Figure 2C ,D) ( Table 4 ).

Subsequently, we assessed the correlation between serum calprotectin and CRP levels, which were assayed using the same Table 5 ).

When comparing laboratory parameters between oxygen therapy groups (R1 and R2) in the patients with COVID-19, the neutrophil count, NLR, peak CRP, peak ferritin, peak PCT, peak D-dimer, and peak BUN were significantly higher in the R2 group than in the R1 group. On the contrary, lymphocyte count and CD4 + T cell count were lower in the R2 group than in the R1 group ( 

Note: Values are expressed as percentage (n) of positive patients.

Abbreviations: aCL, anticardiolipin antibodies; aPL, antiphospholipid antibodies; aPS/PT, anti-phosphatidylserine/prothrombin antibodies; aβ2GPI, anti-β2 glycoprotein I antibodies; COVID-19, coronavirus disease; ELISA, enzyme-linked immunosorbent assay; MFIA, multiplex flow immunoassay; ND, not determined.

*p = 0.002 by chi-square test.

involvement groups (ARDS− and ARDS+), similar patterns were observed for each parameter between ARDS− and ARDS+ groups (Table 6 ).

When assessing the discriminatory performance of each parameter between R1 and R2 groups using ROC curves, the highest AUC was observed for serum calprotectin (AUC 0.91), followed by peak CRP, Figure 3 and Table 8 and are based on data from 85 COVID-19 patients. Additionally, we found no significant difference in the prevalence of "non-criteria aPL," including that between aCL IgA and aβ2GPI IgA, Note: Group R1 included patients who were breathing in room air and patients requiring low flow oxygen therapy (flow rates < 10 L/min). Group R2 included patients requiring high flow oxygen therapy (flow rates ≥ 10 L/min), mechanical ventilation, or extracorporeal membrane oxygenation. In addition, the COVID-19 patients were stratified into two groups by the presence or absence of ARDS during hospitalization.

Abbreviations: ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease; CRP, C-reactive protein; IQR, interquartile range. Note: The highest results of CRP, ferritin, PCT, fibrinogen, D-dimer, and BUN for each patient during hospital admission were defined as the peak levels; in contrast, the lowest values of eGFR and platelet count were defined as minimum levels.

Abbreviations: BUN, blood urea nitrogen; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin.

"n" represents specific patients with available data.

*by Spearman's correlation. Note: Data are presented as median (IQR). "N" represents the total number of stratified patients, whereas "n" represents specific patients with available data. For each patient, the highest levels of CRP, ferritin, PCT, D-dimer, BUN, and fibrinogen were defined as the peak levels; in contrast, the lowest values of eGFR and platelet count were defined as minimum levels.

Abbreviations: ARDS, acute respiratory distress syndrome; BUN, blood urea nitrogen; COVID-19, coronavirus disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin. *by Mann-Whitney test (independent samples).

The discriminatory performance of laboratory parameters by stratified groups of COVID-19 patients pneumonia, 32 and idiopathic pulmonary fibrosis, 33 reaching a maximum overestimation of 5-10 h. 41 Furthermore, there is a report suggesting distinct exercise intensity-dependent changes in calprotectin following extreme physical exertion. 42 Pre-analytical standardization in sample collection and processing, as well as proper validation of reference intervals, would be mandatory in future research.

In this study, representative data for conventionally used parameters were selected based on their peak levels (CRP, ferritin, PCT, and D-dimer) or minimal levels (platelet count and eGFR), with multiple measurements during each patient's hospital admission.

Although serum calprotectin levels were measured at one point in sera collected during the relatively early phase of COVID-19 illness,

calprotectin's performance surpassed other parameters' performances in predicting COVID-19 severity. Therefore, we suggest that serum calprotectin is a potentially valuable biomarker for predicting the clinical severity of COVID-19, independently or in combination with other conventional parameters. Nevertheless, further studies using multivariate analyses will be needed to identify independent predictors of severe disease and define the best combination of markers to facilitate risk stratification and management of COVID-19

cases.

In summary, the prevalence of clinically significant aPL among 

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Coagulopathy and antiphospholipid antibodies in patients with COVID-19

Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism

Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis

Circulating calprotectin as a biomarker of COVID-19 severity

Anti-phosphatidylserine/ prothrombin antibodies: an additional diagnostic marker for APS?

Acute respiratory distress syndrome: the Berlin Definition

Antibodies to serine proteases in the antiphospholipid syndrome

Anti-phospholipid antibodies in COVID-19 are different from those detectable in the antiphospholipid syndrome

Frequent Falsepositive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin

Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?

Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA)

Influence of anticardiolipin and anti-β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification

Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH

Reporting of cardiac troponin -problems with the 99th population percentile

Antiphospholipid antibodies and infections

Systematic review of case reports of antiphospholipid syndrome following infection

Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Extracellular DNA traps promote thrombosis

In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis

Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Targeting potential drivers of COVID-19: neutrophil extracellular traps

Holocrine secretion of calprotectin: a neutrophilmediated defense against Candida albicans?

Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans

Calprotectin in rheumatic diseases: a review

Myeloid-related protein 8/14 levels in rheumatoid arthritis: marker of disease activity and response to methotrexate

Calprotectin and calgranulin C serum levels in bacterial sepsis

Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus

Calprotectin, a new biomarker for diagnosis of acute respiratory infections

Inflammatory biomarkers are associated with aetiology and predict outcomes in communityacquired pneumonia: results of a 5-year follow-up cohort study

Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts

COVID-19 and the clinical hematology laboratory

Hematological findings and complications of COVID-19

COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome?

Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19

Neutrophil calprotectin identifies severe pulmonary disease in COVID-19

Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients

Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis

Critical role of preanalytical aspects for the measurement of circulating calprotectin in serum or plasma as a biomarker for neutrophil-related inflammation

Serum calprotectin, a marker of neutrophil activation, and other mediators of inflammation in response to various types of extreme physical exertion in healthy volunteers